Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.
24 Mar 2026 15:32 CET
Issuer
SARTORIUS STEDIM BIOTECH
|
Sartorius Stedim Biotech SA
/ Key word(s): AGM/EGM
Aubagne, France | March 24, 2026
Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A. At today’s combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A., shareholders granted discharge to all Directors by a large majority. Effective March 24, 2026, the Board of Directors of Sartorius Stedim Biotech S.A. is composed of: Michael Grosse (Chairman), René Fáber (CEO), Pascale Boissel, Susan Dexter, Cécile Dussart, Abdelatif Zeroual (Director Representing Employees), Anne-Marie Graffin (Lead Independent Director), Lothar Kappich, and Christopher Nowers.
The shareholders also approved all other resolutions by a large majority, including the proposal to pay a dividend of 0.69 euros per share for fiscal 2025. The total payout will be 67.1 million euros. The dividend will be paid as from April 2, 2026.
Further Information Shareholders' Meeting | Sartorius Stedim Biotech S.A. Company images CVs and images of the Directors Financial calendar April 23, 2026 | Publication of the first quarter results for January to March 2026 July 23, 2026 | Publication of half-year results for January to June 2026 October 22, 2026 | Publication of nine-month results January to September 2026 A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3 billion euros. Currently, more than 10,200 employees are working for customers around the globe.
Contact Verena Sattel External Communications +49 551 308 9261 verena.sattel@sartorius.com Attachment File: Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A. | Media Release
Dissemination of a Financial Wire News, transmitted by EQS Group. |
| Language: | English |
| Issuer: | Sartorius Stedim Biotech SA |
| Avenue de Jouques | |
| 13781 Aubagne | |
| France | |
| Phone: | +33 44 284 5600 |
| E-mail: | sartorius.presse@sartorius.com |
| Internet: | www.sartorius.com |
| ISIN: | FR0013154002 |
| EQS News ID: | 2296728 |
| End of Announcement - EQS News Service | |
|
|
2296728 24-March-2026 CET/CEST
Source
Sartorius Stedim Biotech SA
Provider
EQS Group
Company Name
SARTORIUS STED BIO, SARTORIUS STEDIM BIOTECH
ISIN
FR0013154002, FR0013154002
Symbol
DIM, 4DIM
Market
Euronext